We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Research · February 03, 2020

Efficacy and Safety of Approved First-Line TKI Treatments in mRCC

Advances in Therapy


Additional Info

Disclosure statements are available on the authors' profiles:

Advances in Therapy
Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis
Adv Ther 2019 Dec 14;[EPub Ahead of Print], KM Manz, K Fenchel, A Eilers, J Morgan, K Wittling, WCM Dempke

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading